India Pharma Outlook Team | Monday, 23 February 2026
BahiaFarma has partnered with Biocon Biologics Ltd. and Bionovis under the BahiaFarma, Biocon, Bionovis Sign Cancer Drug MoU to jointly develop and manufacture a critical cancer therapy.
The agreement focuses on Pertuzumab, a biologic drug used to treat HER2-positive metastatic breast cancer, and is aimed at expanding access to advanced oncology treatment across Brazil’s public healthcare network.
The partnership will cover the development of the active pharmaceutical ingredient and the production of the finished drug product. It also includes technology transfer, regulatory alignment, and specialized workforce training to strengthen local manufacturing capabilities.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
By combining Biocon’s global experience in biologics with Brazil’s established pharmaceutical infrastructure, the companies plan to support reliable and cost-effective domestic production of complex cancer medicines.
The MoU was signed during the visit of Brazilian President Luiz Inácio Lula da Silva to India at the India-Brazil Business Forum organized by the Federation of Indian Chambers of Commerce and Industry. The collaboration is expected to benefit Sistema Único de Saúde, Brazil’s public health system, by improving long-term supply security for essential oncology drugs.
Through this BahiaFarma, Biocon, Bionovis Sign Cancer Drug MoU, the three partners are reinforcing strategic pharmaceutical ties between India and Brazil while working to make life-saving biologic therapies more accessible and affordable for patients who depend on public healthcare services.
